Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 12.63 HKD -3.81% Market Closed
Market Cap: 12.5B HKD
Section:
 

Relative Value

The Relative Value of one Ascletis Pharma Inc stock under the Base Case scenario is hidden HKD. Compared to the current market price of 12.63 HKD, Ascletis Pharma Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Ascletis Pharma Inc Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

4 660.5
P/S
P/S
Price to Sales
4 660.5
vs History
6
vs Industry
4
Median 3Y
74.7
Median 5Y
40.1
Industry
7.9
Forward
7 920.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-9.6
Median 5Y
-17.7
Industry
23.7
Forward
-27.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-13.9
Median 5Y
-22.2
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13.3
Median 5Y
-20.7
Industry
23.8
More Details
5.9
P/B
P/B
Price to Book Value
5.9
vs History
3
vs Industry
25
Median 3Y
0.9
Median 5Y
1
Industry
3.3
More Details
3 900.7
EV/S
EV/S
Enterprise Value to Sales
3 900.7
vs History
4
vs Industry
4
Median 3Y
-1.9
Median 5Y
-8.5
Industry
8.3
Forward
6 629.2
More Details
10 772.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
10 772.4
vs History
3
vs Industry
9
Median 3Y
60.7
Median 5Y
15.6
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
12
Median 3Y
0.3
Median 5Y
-5.7
Industry
6.4
Forward
-22.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
11
Median 3Y
0.3
Median 5Y
-4.9
Industry
7
Forward
-21.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
13
Median 3Y
0.7
Median 5Y
-6.9
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
10
Median 3Y
0.7
Median 5Y
-6.6
Industry
6.5
More Details
46.1
EV/IC
EV/IC
Enterprise Value to IC
46.1
vs History
3
vs Industry
8
Median 3Y
-0.6
Median 5Y
0.2
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Ascletis Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Ascletis Pharma Inc
HKEX:1672
12.2B HKD 4 660.5 -42.6 -23.7 -23.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 786 100.8 -160 580.3 -194 995.7 -192 770.6
US
Abbvie Inc
NYSE:ABBV
397.8B USD 6.7 169.4 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
175.2B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.4B USD 9.8 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 085.2 -532.1 -579.4 -563.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.1 16.3 18.5
AU
CSL Ltd
ASX:CSL
84.2B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
44.5B EUR 14.5 34.1 58.8 60.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.1B USD 16.2 1 195.5 157 190.4
P/S Multiple
Revenue Growth P/S to Growth
CN
Ascletis Pharma Inc
HKEX:1672
Average P/S: 3 072 083
4 660.5
312%
14.9
FR
Pharnext SCA
OTC:PNEXF
33 786 100.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 085.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
46%
0.4
P/E Multiple
Earnings Growth PEG
CN
Ascletis Pharma Inc
HKEX:1672
Average P/E: 188.7
Negative Multiple: -42.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 580.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 195.5
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Ascletis Pharma Inc
HKEX:1672
Average EV/EBITDA: 39.3
Negative Multiple: -23.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 995.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
58.8
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
157
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Ascletis Pharma Inc
HKEX:1672
Average EV/EBIT: 45.3
Negative Multiple: -23.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 770.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.4
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.